240 related articles for article (PubMed ID: 34532285)
1. BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer.
Demerlé C; Gorvel L; Olive D
Front Oncol; 2021; 11():682007. PubMed ID: 34532285
[TBL] [Abstract][Full Text] [Related]
2. Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors.
Demerlé C; Gorvel L; Mello M; Pastor S; Degos C; Zarubica A; Angelis F; Fiore F; Nunes JA; Malissen B; Greillier L; Guittard G; Luche H; Barlesi F; Olive D
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37230538
[TBL] [Abstract][Full Text] [Related]
3. Fragments of gD Protein as Inhibitors of BTLA/HVEM Complex Formation-Design, Synthesis, and Cellular Studies.
Kuncewicz K; Battin C; Sieradzan A; Karczyńska A; Orlikowska M; Wardowska A; Pikuła M; Steinberger P; Rodziewicz-Motowidło S; Spodzieja M
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33238640
[TBL] [Abstract][Full Text] [Related]
4. Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding.
Spodzieja M; Kuncewicz K; Sieradzan A; Karczyńska A; Iwaszkiewicz J; Cesson V; Węgrzyn K; Zhukov I; Maszota-Zieleniak M; Michielin O; Speiser DE; Zoete V; Derré L; Rodziewicz-Motowidło S
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963646
[TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of BTLA and PD-1 can enhance therapeutic efficacy of paclitaxel on intraperitoneally disseminated tumors.
Sun WZ; Lin HW; Chen WY; Chien CL; Lai YL; Chen J; Chen YL; Cheng WF
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37463789
[TBL] [Abstract][Full Text] [Related]
6. A herpesvirus entry mediator mutein with selective agonist action for the inhibitory receptor B and T lymphocyte attenuator.
Šedý JR; Balmert MO; Ware BC; Smith W; Nemčovičova I; Norris PS; Miller BR; Aivazian D; Ware CF
J Biol Chem; 2017 Dec; 292(51):21060-21070. PubMed ID: 29061848
[TBL] [Abstract][Full Text] [Related]
7. Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy.
Sordo-Bahamonde C; Lorenzo-Herrero S; Granda-Díaz R; Martínez-Pérez A; Aguilar-García C; Rodrigo JP; García-Pedrero JM; Gonzalez S
Mol Cancer; 2023 Aug; 22(1):142. PubMed ID: 37649037
[TBL] [Abstract][Full Text] [Related]
8. Blockade of HVEM for Prostate Cancer Immunotherapy in Humanized Mice.
Aubert N; Brunel S; Olive D; Marodon G
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34208480
[TBL] [Abstract][Full Text] [Related]
9. HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma.
Malissen N; Macagno N; Granjeaud S; Granier C; Moutardier V; Gaudy-Marqueste C; Habel N; Mandavit M; Guillot B; Pasero C; Tartour E; Ballotti R; Grob JJ; Olive D
Oncoimmunology; 2019; 8(12):e1665976. PubMed ID: 31741766
[TBL] [Abstract][Full Text] [Related]
10. Targeting BTLA with the peptide inhibitor HVEM(14-39) - A new way to restore the activity of T cells in melanoma.
Wojciechowicz K; Kuncewicz K; Rutkowski J; Jassem J; Rodziewicz-Motowidło S; Wardowska A; Spodzieja M
Biomed Pharmacother; 2024 Jun; 175():116675. PubMed ID: 38733770
[TBL] [Abstract][Full Text] [Related]
11. The BTLA-HVEM complex - The future of cancer immunotherapy.
Wojciechowicz K; Spodzieja M; Wardowska A
Eur J Med Chem; 2024 Mar; 268():116231. PubMed ID: 38387336
[TBL] [Abstract][Full Text] [Related]
12. B- and T-Lymphocyte Attenuator in Systemic Lupus Erythematosus Disease Pathogenesis.
Vendel AC; Jaroszewski L; Linnik MD; Godzik A
Clin Pharmacol Ther; 2024 Apr; ():. PubMed ID: 38676311
[TBL] [Abstract][Full Text] [Related]
13. BTLA-derived peptides as inhibitors of BTLA/HVEM complex formation - design, synthesis and biological evaluation.
Kuncewicz K; Bojko M; Battin C; Karczyńska A; Sieradzan A; Sikorska E; Węgrzyn K; Wojciechowicz K; Wardowska A; Steinberger P; Rodziewicz-Motowidło S; Spodzieja M
Biomed Pharmacother; 2023 Sep; 165():115161. PubMed ID: 37473684
[TBL] [Abstract][Full Text] [Related]
14. Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.
Spodzieja M; Lach S; Iwaszkiewicz J; Cesson V; Kalejta K; Olive D; Michielin O; Speiser DE; Zoete V; Derré L; Rodziewicz-Motowidło S
PLoS One; 2017; 12(6):e0179201. PubMed ID: 28594868
[TBL] [Abstract][Full Text] [Related]
15. T cell intrinsic heterodimeric complexes between HVEM and BTLA determine receptivity to the surrounding microenvironment.
Cheung TC; Oborne LM; Steinberg MW; Macauley MG; Fukuyama S; Sanjo H; D'Souza C; Norris PS; Pfeffer K; Murphy KM; Kronenberg M; Spear PG; Ware CF
J Immunol; 2009 Dec; 183(11):7286-96. PubMed ID: 19915044
[TBL] [Abstract][Full Text] [Related]
16. Increased BTLA and HVEM in gastric cancer are associated with progression and poor prognosis.
Lan X; Li S; Gao H; Nanding A; Quan L; Yang C; Ding S; Xue Y
Onco Targets Ther; 2017; 10():919-926. PubMed ID: 28243127
[TBL] [Abstract][Full Text] [Related]
17. Modulation of T cell proliferation through the LIGHT-HVEM-BTLA cosignaling pathway.
Cheung TC
Recent Pat DNA Gene Seq; 2009; 3(3):177-82. PubMed ID: 19702559
[TBL] [Abstract][Full Text] [Related]
18. BTLA/HVEM Signaling: Milestones in Research and Role in Chronic Hepatitis B Virus Infection.
Yu X; Zheng Y; Mao R; Su Z; Zhang J
Front Immunol; 2019; 10():617. PubMed ID: 30984188
[TBL] [Abstract][Full Text] [Related]
19. BTLA inhibition has a dominant role in the
Battin C; Leitner J; Waidhofer-Söllner P; Grabmeier-Pfistershammer K; Olive D; Steinberger P
Front Immunol; 2022; 13():956694. PubMed ID: 36081508
[TBL] [Abstract][Full Text] [Related]
20. Unconventional ligand activation of herpesvirus entry mediator signals cell survival.
Cheung TC; Steinberg MW; Oborne LM; Macauley MG; Fukuyama S; Sanjo H; D'Souza C; Norris PS; Pfeffer K; Murphy KM; Kronenberg M; Spear PG; Ware CF
Proc Natl Acad Sci U S A; 2009 Apr; 106(15):6244-9. PubMed ID: 19332782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]